![]() |
Technical Support
(877) SEPAX-US, press 3 ![]() TechSupport@sepax-tech.com |
![]() ![]() |
By Separation Mode | By Brand | By Sample Based Application | |
Size Exclusion Ion Exchange Hydrophobic Interaction Ion Exclusion Sub-2 UHPLC Purification Reversed Phase Mixed-mode Phase HILIC View All |
SEC-MALS Unix / Unix-C Zenix / Zenix-C SRT / SRT-C SRT-10 / SRT-10C Proteomix HIC / IEX Antibodix Carbomix Proteomix RP View All |
ADC Antibody Biosimilar Carbohydrate Cell Lysate DNA/RNA Fusion Protein Glycan Glycoprotein Heparin |
Insulin Membrane Protein Organic Acid PEG/PEGylated Protein Peptide Polymer Protein Vaccine/VLP Others |
How May We Help You?
How May We Help You?
How May We Help You?
Your question has been submitted.
We will respond back to you shortly.
We will respond back to you shortly.
How May We Help You?
Please fill out all required fields.
Sample: AllAll
|
Application Note
App ID | Title |
a1t0h0000026Bkh | Literature Reference: High-throughput characterization of virus-like particles by interlaced size-exclusion chromatography | Size ExclusionSRTPore Size SelectionHPLC1
AAV6 | Advanced SRT SEC 750 A for Optimal AAV Analysis | Size ExclusionSRTPore Size Selection@Method OptimizationHPLC1
AAV7 | Analytical Characterization of AAV 2/8/9 Serotypes | Size ExclusionSRTPore Size Selection@Method OptimizationHPLC1
Accessories | Accessories - View more details | AccessoriesAccessoriesAccessoriesHPLC1
AE1001 | Gradient Impact on Peptide Analysis on Antibodix WCX | Ion ExchangeAntibodixMethod OptimizationHPLC1
AM1001 | MAb on Antibodix vs. Competitor WCX | Ion ExchangeAntibodixCompetition Comparison@Resolution@Charge VariantsHPLC1
AM1002 | MAb Charge Variants on Antibodix WCX NP10 | Ion ExchangeAntibodixCharge VariantsHPLC1
AM1003 | Antibodix WCX NP3 vs. NP1.7 | Ion ExchangeAntibodixParticle Size Impact@Fast Assay@Charge VariantsHPLC@UHPLC1
AM1004 | Antibodix WCX NP3 vs. NP5 vs. NP10 | Ion ExchangeAntibodixParticle Size Impact@Charge VariantsHPLC1
AM1005 | MAb Charge Variants on Antibodix WCX NP5 | Ion ExchangeAntibodixCharge VariantsHPLC1
AM1006 | MAb on Antibodix WCX Method Optimization-Gradient | Ion ExchangeAntibodixMethod Optimization@Charge VariantsHPLC1
AM1007 | MAb on Antibodix WCX Method Optimization-Initial Salt Impact | Ion ExchangeAntibodixMethod Optimization@Charge VariantsHPLC1
AM1008 | MAb on Antibodix WCX Method Optimization-pH Impact | Ion ExchangeAntibodixMethod Optimization@Charge VariantsHPLC1
AM1009 | Two MAb Comparison on Antibodix WCX NP3 | Ion ExchangeAntibodixCharge Variants@Fast AssayHPLC1
AM1010 | MAb on Antibodix WCX NP5 | Ion ExchangeAntibodixSample Stability Test@Charge VariantsHPLC1
AM1011 | MAb on Antibodix WCX - Particle Size and Loading | Ion ExchangeAntibodixLoading@Particle Size Impact@Fast Assay@Charge VariantsHPLC@UHPLC1
AM1012 | MAb on Antibodix WCX NP1.7 | Ion ExchangeAntibodixMethod Optimization@Fast Assay@Charge VariantsHPLC@UHPLC2
AM1013 | MAb Innovator vs. its Biosimilar on Zenix SEC and Antibodix WCX | Ion Exchange@Size ExclusionAntibodix@ZenixOrthogonal Method@Aggregates@Charge VariantsHPLC2
AP1002 | WCX Separation of Proteins on Antibodix Sub 2 um | Ion ExchangeAntibodixResolution@Fast AssayHPLC@UHPLC2
AP1003 | Particle Size Impact on Protein Separation on Antibodix | Ion ExchangeAntibodixParticle Size ImpactHPLC2
AP1004 | Protein Mixture on Sub 2 µm Antibodix | Ion ExchangeAntibodixResolution@Fast AssayHPLC@UHPLC2
AP1005 | Lifetime Test on Sub 2 µm Antibodix | Ion ExchangeAntibodixColumn StabilityHPLC@UHPLC2
BE1001 | Analysis of a Peptide on Bio-C18 | Reversed Phase@Bio-C18Volatile BufferHPLC@LCMS2
BE1002 | Analysis on Microcystin on Bio-C18 | Reversed PhaseBio-C18Volatile BufferHPLC@LCMS2
BE1003 | Reverse Phase Separation of Biological Samples on Bio-C18 (5um, 300A, 4.6x250mm) | Reversed PhaseBio-C18Reverse Phase Separation of Biological SamplesHPLC2
BE1004 | BE1004- Human serum albumin tryptic digest separation on reversed phase Bio-C18 | Reversed PhaseBio-C18Resolution@Method Optimization@Pore Size SelectionHPLC2
BF1001 | Analysis of Tetracycline on Bio-C8 | Reversed PhaseBio-C8Resolution@Volatile Buffer@Pore Size Selection HPLC@LCMS2
BF1002 | Analysis of Melamine on Bio-C18 | Reversed PhaseBio-C18Resolution@Volatile Buffer@Pore Size Selection HPLC@LCMS2
BF1003 | Analysis of Milk Powder on Bio-C18 | Reversed PhaseBio-C18Resolution@Volatile Buffer@Pore Size Selection HPLC@LCMS2
BH1001 | Analysis of Recombinant Human Growth Hormone on Bio-C4 | Reversed PhaseBio-C4Resolution@Packing Chemistry@Pore Size Selection HPLC@LCMS2
BH1002 | Analysis of Risperidone on Bio-C18 | Reversed PhaseBio-C18Resolution@Volatile Buffer@Pore Size Selection HPLC@LCMS2
BH1003 | Analysis of Nitrazepam and Chlordiazepoxide on Bio-C18 | Reversed PhaseBio-C18Resolution@Volatile Buffer@Pore Size Selection HPLC@LCMS2
BH1004 | Analysis of Puerarin on Bio-C18 | Reversed Phase@Reversed PhaseBio-C18Resolution@Volatile Buffer@Pore Size Selection HPLC@LCMS3
BH1005 | Analysis of Nuodikang capsule on Bio-C18 | Reversed PhaseBio-C18Resolution@Volatile Buffer@Pore Size Selection HPLC@LCMS3
BH1006 | Analysis of Ginsenosides on Bio-C18 | Reversed PhaseBio-C18Resolution@Volatile Buffer@Pore Size Selection HPLC@LCMS3
BM1001 | Literature Reference: Characterization of bispecific antibody production in cell cultures by unique mixed mode size exclusion chromatography | Size ExclusionBioMixAntibody ProductionHPLC3
BM1002 | Bispecific Antibody Separation on Sepax BioMix Mixed Mode SEC Column | Size ExclusionBioMixBispecific Antibody SeparationHPLC3
CC1001 | Carbohydrates Analysis on Carbomix Ca-NP5 | Ion-ExclusionCarbomixResolutionHPLC3
CC1002 | Glucidex Analysis on Carbomix-Ca | Ion-ExclusionCarbomixResolutionHPLC3
CC1003 | Glucose and its Oligomers on Carbomix Ca | Ion-ExclusionCarbomixResolutionHPLC3
CC1004 | Ethanol Production Broth on Carbomix H | Ion-ExclusionCarbomixResolutionHPLC3
CC1005 | Carbohydrates in Beer on Carbomix Ca | Ion-ExclusionCarbomixResolutionHPLC3
CC1006 | Carbohydrates in Food on Carbomix Ca | Ion-ExclusionCarbomixResolutionHPLC3
CC1007 | Carbohydrates Analysis on Carbomix Ca-NP10 | Ion-ExclusionCarbomixResolutionHPLC3
CC1008 | Sugar Mixture on Carbomix Pb | Ion-ExclusionCarbomixResolutionHPLC3
CC1009 | Xylose, Galactose and Mannose on Carbomix Pb | Ion-ExclusionCarbomixResolutionHPLC3
CC1010 | Lactose and Lactulose on Carbomix Pb | Ion-ExclusionCarbomixResolutionHPLC3
CC1011 | Sugar and Sugar Alcohols on Carbomix Pb | Ion-ExclusionCarbomixResolutionHPLC3
CC1012 | Carbohydrates Analysis on Carbomix Na | Ion-ExclusionCarbomixResolutionHPLC4
CC1013 | Carbohydrates Analysis on Carbomix K | Ion-ExclusionCarbomixResolutionHPLC4
CC1014 | Sugar Mixture on Carbomix Ca with ELSD | Ion-ExclusionCarbomixResolutionHPLC4
CC1014a | Sugar Analysis on Carbomix Ca with ELSD vs. RID | Ion-ExclusionCarbomixResolutionHPLC4
CC1015 | Sugar and Sugar Alcohols on Carbomix H vs. Ca | Ion-ExclusionCarbomixResolution@Packing ChemistryHPLC4
CC1016 | Glucose and Fructose on Carbomix H/Ca/Pb | Ion-ExclusionCarbomixResolution@Packing ChemistryHPLC4
CC1017 | Glucose and Fructose in Orange Juice on Carbomix Ca | Ion-ExclusionCarbomixResolutionHPLC4
CC1018 | Fast Analysis of Sugars in Orange Juice on Carbomix Ca | Ion-ExclusionCarbomixFast AssayHPLC4
CC1019 | Sugar Mixture on Carbomix H with ELSD | Ion-ExclusionCarbomixResolutionHPLC4
CC1020 | Sugar Mixture on Carbomix Pb with ELSD | Ion-ExclusionCarbomixResolutionHPLC4
CC1021 | High Loading Separation of Maltotriose and Maltotetraose on Carbomix H | Ion-ExclusionCarbomixLoadingHPLC4
CC1022 | Loading Capacity Test on Carbomix Ca | Ion-ExclusionCarbomixLoadingHPLC4
CC1023 | High Resolution of Carbohydrates on Pb | Ion-ExclusionCarbomixResolutionHPLC4
CC1024 | Temperature Impact on Sugar Separation on Carbomix Ca | Ion-ExclusionCarbomixResolution@Method OptimizationHPLC4
CC1025 | Retention Time Table for Carbomix Phases | Ion-ExclusionCarbomixResolution@Packing Chemistry@Method OptimizationHPLC4
CC1026 | Sucrose, Glucose and Fructose Analysis on Carbomix H-NP10 | Ion-ExclusionCarbomixResolutionHPLC4
CC1027 | Mixed Sugar Separation on Carbomix Pb | Ion-ExclusionCarbomixResolutionHPLC5
CC1028 | Sucrose and IPTG Analysis on Carbomix H-NP5: 8% Column | Ion-ExclusionCarbomixResolutionHPLC5
CC1029 | 5 Min. Fast Sugar, Organic Acid and Alcohol Separation | Ion-ExclusionCarbomixFast Assay@Resolution@Method OptimizationHPLC5
CO1001 | Separation of NGNA and NANA on Two Carbomix H Crosslinkage | Ion-ExclusionCarbomixResolution@Packing ChemistryHPLC5
CO1002 | Fast Analysis of Organic Acids on Carbomix H | Ion-ExclusionCarbomixFast AssayHPLC5
CO1003 | Succinic Acid on Carbomix H with ELSD vs. RID | Ion-ExclusionCarbomixResolutionHPLC5
CO1004 | Sorbitol and Xylitol on Carbomix H/Ca | Ion-ExclusionCarbomixResolutionHPLC5
CO1005 | Sugar and Sugar Alcohols on Carbomix H/Ca/Pb | Ion-ExclusionCarbomixResolution@Packing ChemistryHPLC5
CO1006 | Analysis of Alcohols on Carbomix H | Ion-ExclusionCarbomixResolutionHPLC5
CO1007 | Organic Acids on Carbomix H | Ion-ExclusionCarbomixResolutionHPLC5
CO1009 | Malic Acid on Carbomix H | Ion-ExclusionCarbomixResolutionHPLC5
CO1010 | Food Softeners on Carbomix Ca | Ion-ExclusionCarbomixResolutionHPLC5
CO1011 | Formic and Levulinic Acid on on Two Carbomix H Crosslinkage | Ion-ExclusionCarbomixResolutionHPLC5
CO1012 | Organic Acids, Sugar and Alcohols on Carbomix H | Ion-ExclusionCarbomixMethod OptimizationHPLC5
CO1013 | Trehalose and Citric Acid Analysis on Carbomix H-NP10: 5% column | Ion-ExclusionCarbomixResolutionHPLC5
CO1014 | 3 Min. Fast Organic Acid Analysis with Lifetime Test | Ion-ExclusionCarbomixFast Assay@Column Stability@ResolutionHPLC5
EE1001 | mPEG-peptide on Zenix and Zenix-C SEC | Size ExclusionZenix-C@ZenixPacking ChemistryHPLC6
EE1002 | Exenatide Analysis on Zenix SEC-80 | Size ExclusionZenixExenatide AnalysisHPLC6
EE1003 | Transfer Factor Oral Solution SEC Separation | Size ExclusionZenix@Zenix-CParticle Size Impact@Pore Size Selection@Packing ChemistryHPLC6
EE1004 | Insulin SEC Analysis | Size ExclusionZenix-CMethod Optimization@Pore Size Selection@Resolution@Lot to Lot@Sample Stability Test@Column Stability@AggregatesHPLC6
EE1005 | SEC Analysis of Insulin and HMW Aggregates | Size Exclusion@Size Exclusion@Size ExclusionZenix-CMethod Optimization@Pore Size Selection@Resolution@Lot to Lot@Sample Stability Test@Column Stability@AggregatesHPLC6
EE1006 | Glucagon SEC Separation in 45% Acetonitrile with 0.1% TFA | Size ExclusionZenix-CVolatile Buffer@Method Optimization@ResolutionHPLC@LCMS6
EG1000 | PEGylated Protein Separation- SEC and RP | Size Exclusion@Reversed PhaseZenix@Proteomix@Bio-C4@Bio-C18PEGylated Protein SeparationHPLC6
EG1001 | Sepax PEGylated Lysozyme- SEC, RP, IEX and MM | Size Exclusion@Reversed Phase@Ion Exchange@MMZenix@Proteomix@Bio-C4@Bio-C18PEGylated LysozymeHPLC6
EH1001 | Analysis of Dextran Sulfate on Zenix-C SEC-300 (3µm, 300Å, 7.8x300mm) | Size ExclusionZenix-CAnalysis of Dextran SulfateHPLC6
EM1001 | SEC Packing Chemistry Impact on MAb Separation | Size ExclusionZenix@Zenix-CPacking Chemistry@AggregatesHPLC6
EM1002 | ADC Analysis on Zenix-C SEC | Size ExclusionZenix@Zenix-CResolution@Packing Chemistry@Aggregates@Method OptimizationHPLC6
EM1003 | Herceptin Analysis on ZenixTM SEC-300 (7830) | Ion ExchangeZenixHerceptin AnalysisHPLC6
EM1004 | Herceptin-Lysine ADC Analysis by Zenix-C and TSKgel | Size ExclusionZenix-CCompetition Comparison@Resolution@Packing Chemistry@Aggregates@Method OptimizationHPLC6
EM1005 | Rituximab analysis using Zenix-C Light Scattering SEC -MALS 300 | Size ExclusionZenix-CResolution@Purification@Optimization@SEC-MALSHPLC6
EM1006 | EM1006 - Bispecific mAb SEC analysis | Size ExclusionZenixResolution@Aggregates@Pore Size SelectionHPLC6
EM1007 | Analytical Characterization of Monoclonal Antibody IgG2 | Size Exclusion@Ion Exchange@Hydrophobic Interaction@Reversed PhaseProteomix@Zenix-C@Unix-C@Proteomix SCX@Proteomix HIC@Proteomix RPResolution@Particle Size Impact@SEC-MALS@ Hydrophobicity@Charge Variants@Aggregates@Orthogonal MethodHPLC6
EM1008 | Site Specific Trastuzumab Antibody Drug Conjugates | SECZenix-CSECHPLC7
EP1001 | Fusion Protein Separation on Zenix and Zenix-C 300 | Size ExclusionZenix-C@ZenixAggregates@Method Optimization@Packing ChemistryHPLC7
EP1002 | DTT and EDTA Effect on SEC Protein Separation | Size ExclusionZenix-CMethod OptimizationHPLC7
EP1003 | HSA Fusion Protein Separation on Zenix and Zenix-C 300 | Size ExclusionZenix-C@ZenixMethod Optimization@Packing Chemistry@AggregatesHPLC7
EP1004 | Fusion Protein Separation on SEC and SAX | Size Exclusion@Size Exclusion@Size Exclusion@Ion ExchangeZenix-C@Zenix@ProteomixMethod Optimization@Packing Chemistry@Aggregates@Orthogonal Method@ResolutionHPLC7
EP1005 | 2.1 mm ID SEC for Protein Separation | Size ExclusionZenix-C Volatile Buffer@Method OptimizationHPLC@LCMS@NanoLC7
EP1006 | Human Serum Separation on Zenix-C and SAX | Ion Exchange@Size ExclusionProteomix@Zenix-CResolution@Orthogonal MethodHPLC7
EP1007 | Protein Standards on Zenix-C and SRT-C SEC-300 | Size Exclusion@Size ExclusionZenix-C@SRT-CParticle Size Impact HPLC7
EP1008 | Eylea-Aflibercept | Size ExclusionZenix-CAggregates@Method Optimization@ResolutionHPLC7
EV1001 | Liposome Encapsulated Drugs Analysis on SEC | Size ExclusionZenix-CPacking Chemistry@Method Optimization@ResolutionHPLC7
FM1001 | Sepax's ProAqa Excel Protein A Affinity Column for Fast Antibody Titer Determination | AffinityProAqa ExcelFast AssayHPLC@UHPLC@FPLC7
GA1001 | Amino Acids on GP-C18 | Reversed PhaseGP-C18Resolution@Volatile BufferHPLC@LCMS7
GI1001 | Analysis of Mixed Acids with Sepax GP-C18 | Reversed PhaseGP-C18Reversed PhaseHPLC7
HICM1001 | ADC/MAb Separation on Proteomix HIC | Hydrophobic InteractionProteomix@Proteomix HICLot to Lot@Competition Comparison@ResolutionHPLC7
HICM1002 | MAb Loading on Proteomix HIC Butyl-NP10 | Hydrophobic InteractionProteomix@Proteomix HICLoadingHPLC7
HICM1003 | MAb Loading from Analytical to Prep HIC | Hydrophobic Interaction@Hydrophobic InteractionProteomix@Proteomix HICLoadingHPLC7
HICM1004 | MAb hydrophobicity screening on Proteomix HIC Butyl-NP5 | Hydrophobic InteractionProteomix@Proteomix HICHydrophobicityHPLC8
HICM1005 | Erbitux and Rituximab Monoclonal Antibody Separation on Proteomix HIC Butyl NP5 | Hydrophobic InteractionProteomix@Proteomix HICResolution@HydrophobicityHPLC8
HICM1006 | Intact and Oxidized Monoclonal Antibody Separation on Proteomix HIC | Hydrophobic InteractionProteomix@Proteomix HICCompetition Comparison@Resolution@Method Optimization HPLC@UHPLC8
HICM1008 | Intact and Oxidized MAb Analysis on Proteomix HIC Butyl 1.7 µm | Hydrophobic InteractionProteomix@Proteomix HICCompetition Comparison@Resolution@Method Optimization@Particle Size ImpactHPLC@UHPLC8
HICM1009 | HICM1009- Mab Analysis on Proteomix® HICNP5 phases (4603) | Hydrophobic InteractionProteomix@Proteomix HICResolution@Hydrophobicity@Packing ChemistryHPLC8
HICM1010 | Analytical Characterization of NIST MAb by Hydrophobic Interaction Chromatography (HIC) | Hydrophobic InteractionProteomix HICMethod Optimization@Resolution@Orthogonal MethodHPLC8
HICP1001 | HICP1001 - Fusion protein Analysis on Proteomix® HICBu-NP5 ( 4603 ) | Hydrophobic InteractionProteomix@Proteomix HICResolution@Orthogonal MethodHPLC8
JL1001 | Organic Polymer Analysis on Sepax MonoGPC | Size ExclusionMonoGPCPore Size Selection@Method Optimization@Packing Chemistry@ResolutionHPLC8
KM1001 | Purification of Bispecific Antibody by Sepax MabPurix P45 Protein A Affinity | AffinityMabPurix Protein AN/AHPLC8
KM1002 | Purification of Tribody by Sepax MabPurix A45 Protein A Affinity | AffinityMabPurix Protein AN/AHPLC8
KM1003 | Technical Specification - MabPurix Protein A Affinity vs. Other Brands | AffinityMabPurix Protein AN/AHPLC8
KM1004 | Monoclonal Antibody Purification by Sepax MabPurix A65 Protein A Affinity | AffinityMabPurix Protein AN/AHPLC8
LR2022021043 | Literature Reference: Titer measurement of HIV-1 envelope trimeric glycoprotein in cell culture media by a new tandem ion exchange and size exclusion chromatography (IEC-SEC) method. | SECSRT SEC-300Purification@OptimizationUHPLC8
LR202202105 | Literature Reference: In-situ Reverse Phased HPLC Analysis of Intact Antibody-Drug Conjugates | Reversed PhaseProteomix RPADC (Antibody Drug Conjugate)HPLC8
LR2022021051 | Literature Reference: Liquid chromatography methods for the separation of short RNA oligonucleotides | IEXProteomixOligonucleotide Separation, Optimization,HPLC8
LR2022021052 | Literature Reference: Engineering circular RNA for potent and stable translation in eukaryotic cells | Size ExclusionSRTSize Exclusion@RNA Separation on Wide Pore Column@Separation of RNAHPLC8
LR2022021086 | Literature Reference: A novel mechanism for the loss of mRNA activity in lipid nanoparticle delivery systems | SECZenixRNA SeparationUPLC9
LR2022021101 | Literature Reference: RNA circles with minimized immunogenicity as potent PKR inhibitors | Size ExclusionSRTSize Exclusion@RNA Separation on Wide Pore Column@Separation of RNAHPLC9
LR2022021104 | Literature Reference: Intratumoral Delivered Novel Circular mRNA Encoding Cytokines for Immune Modulation and Cancer Therapy | Size ExclusionSRTSize Exclusion@RNA Separation on Wide Pore Column@Separation of RNAFPLC9
LR2022021128 | Literature Reference: Engineered circular ADAR-recruiting RNAs increase the efficiency and fidelity of RNA editing in vitro and in vivo | Size ExclusionSRTSize Exclusion@RNA Separation on Wide Pore Column@Separation of RNAHPLC9
LR2022021136 | Literature Reference: Design and application of circular RNAs with protein-sponge function | Size ExclusionSRTSize Exclusion@RNA Separation on Wide Pore Column@Separation of RNAHPLC9
LR2022021138 | Literature Reference: Impact of Time Out of Intended Storage and Freeze-thaw Rates on the Stability of Adeno-associated Virus 8 and 9 | SECSRTPore Size Selection, OptimizationHPLC9
LR202202139 | Literature Reference: A novel twin-column continuous chromatography approach for separation and enrichment of monoclonal antibody charge variants | IEXProteomix@AntibodixPurificationHPLC@FPLC9
LR202202170 | Literature Reference: Single Domain Antibodies as Carriers for Intracellular Drug Delivery: A Proof of Principle Study | SECZenix-C SEC-300ADC, LC-MS Analysis, Organix Mobile Phase ACN:TFA:WaterHPLC@LC-MS9
LR202202197 | Literature Reference: Analytical and Functional Similarity Assessment of ABP 710, a Biosimilar to Infliximab Reference Product | Ion ExchangeProteomixOrthogonal Method@Charge Variants@Antibody Production@MAb FragmentHPLC9
LR2022024 | Literature Reference: Characterization and Identification of Adeno of Adena Associated Vectors by SEC and MALS | SECSRTSEC-MALS@AggregatesHPLC@SEC-MALS9
LR202202580 | Literature Reference: EFab domain substitution as a solution to the light-chain pairing problem of bispecific antibodies | Size ExclusionZenixBispecific Antibody Separation@Aggregates@Fast Assay@MAb FragmentUHPLC9
LR20220261 | Literature Reference: Characterization of Fc-fusion protein aggregates derived from extracellular domain disulfide bond rearrangements | SECSRTAggregates, Method Optimization, Optimization, SEC-MALS, Oligonucleotide Separation, Fusion Protein SeparationHPLC9
LR202202620 | Literature Reference: Design and Characterization of Homogenous Antibody-drug Conjugates with a Drug-to-Antibody Ratio of One Prepared Using an Engineered Antibody and a Dual-maleimide Pyrrolobenzodiazepine Dimer | Hydrophobic InteractionProteomix HICHydrophobic Interaction, Site-Specific ADC, DARHPLC9
LR202202664 | Literature Reference: Homogeneous Antibody-Drug Conjugates: DAR 2 Anti-HER2 Obtained by Conjugation on Isolated Light Chain Followed by mAb Assembly | Size Exclusion, Hydrophobic InteractionZenix-C SEC-300@Proteomix HIC Butyl-NP5ADC, Heavy Chain and Light Chain AnalysisHPLC@HPLC9
LR202202670 | Literature Reference: Site-Specific Conjugation of the Indolinobenzodiazepine DGN549 to Antibodies Affords Antibody-Drug Conjugates with an Improved Therapeutic Index as Compared with Lysine Conjugation | Hydrophobic InteractionProteomix HICHydrophobic Interaction, ADCHPLC9
LR202202962 | Literature Reference: RNA Circularization Diminishes Immunogenicity and Can Extend Translation Duration In Vivo | Size ExclusionSRTSize Exclusion@RNA Separation on Wide Pore Column@Separation of RNAHPLC9
LR2022041207 | Literature Reference: Mechanistic Studies and Formulation Mitigations of Adeno-associated Virus Capsid | SECSRTAggregates@method optimizationUV10
LR2022051235 | Literature Reference: Development of a robust and semi-automated two-step antibody purification process | Size ExclusionSRT-10CPurification, Method OptimizationAKTA Pure10
LR2022081354 | Design and Characterization of Immune-Stimulating Imidazo45-cquinoline Antibody Drug Conjugates | RPProteomix RPADC Free Drug Analysis on Sepax Analytical RP ColumnHPLC@UHPLC10
LR2023011394 | Literature Reference: Hiding Payload Inside the IgG Fc Cavity Significantly Enhances the Therapeutic Index of Antibody Drug Conjugates | SECZenix-C SEC-300gsADCs@Glycosite-Specific Antibody Drug@Site-Specific ADCs on Sepax Analytical SEC HPLC10
LR2023031428 | Literature Reference: Application of Size Exclusion Chromatography with Multi-Angle Light Scattering in the Analytical Development of a Preclinical Stage Gene Therapy Program | Size ExclusionSRTSize Exclusion Chromatography@AAV@SRTHPLC10
LR2023101483 | Literature Reference: Novel Thienoduocarmycin-trastuzumab ADC Demonstrates Strong Anti-tumor Efficacy | HICProteomix HICThienoduocarmycin-trastuzumab ADCHPLC10
LR2023121487 | Literature Reference: Circular mRNA-based TCR-T Offers a Safe and Effective Therapeutic Strategy for Treatment of Cytomegalovirus Infection | SECSRTCircular mRNA-basedHPLC10
LR2024021488 | Literature Reference: Structural Insights Into CXCR4 Modulation and Oligomerization | Size ExclusionZenix-CSize Exclusion, Membrane protein separation, GPCRHPLC10
LR2024021489 | Literature Reference: Absolute Quantitation of Binding Antibodies from Clinical Samples | Size ExclusionUnix-CSize Exclusion, VLP/Virus/Vaccine, AntibodyHPLC10
LR2024021491 | Literature Reference: Online Multimethod Platform for Comprehensive Characterization of Monoclonal Antibodies in Cell Culture Fluid From a Single Sample Injection - Intact Protein Workflow | Ion ExchangeProteomix SCX-NP3Charge Variant, SEC and Mass, Characterization of MabsUV10
LR2024051502 | Literature Reference: Development of a Fast Method Using Inductively Coupled Plasma Mass Spectrometry Coupled with High-Performance Liquid Chromatography and Exploration of the Reduction Mechanism of Cr(VI) in Food | IEXProteomix WAX-NP5Ultra Fast IEX Analysis of MetalHPLC10
LR2024051506 | Literature Reference: Mosaic Quadrivalent Influenza Vaccine Single Nanoparticle Characterization | Size ExclusionSRTQuantitative Analysis, Vaccine Construct, Nanoparticle Valency, Aggregate Analysis, Method OptimizationUHPLC10
LR2024051507 | Literature Reference: Structure-function Relationship Study for Sulfated Protein Therapeutics Using Hydrophobic Interaction Chromatography and Mass Spectrometry | Hydrophobic InteractionProteomix HIC HIC, Mass Spec, BsMabHPLC10
LR2024071523 | Literature Reference: In-Depth Characterization for Methionine Oxidization in Complementary Domain Region by Hydrophobic Interaction Chromatography | Hydrophobic InteractionProteomix HICMonoclonal AntibodiesHPLC10
LR2024081527 | Literature Reference: Universal Paramyxovirus Vaccine Design by Stabilizing Regions Involved in Structural Transformation of the Fusion Protein | Size ExclusionUnix-C SEC-300Paramyxovirus Vaccine, RV3 Fusion (F) protein, SEHPLC10
LR2025011549 | Literature Reference: A broad spectrum Shigella vaccine based on VirG53-353 multiepitope region produced in a cell-free system | SECSRTEpitopes from overlapping 10mer regionsHPLC10
LR2025011554 | Literature Reference: Structure-guided discovery of viral proteins that inhibit host immunity | Size ExclusionSRTSEC, ProteinHPLC11
LR2025011555 | Literature Reference: Process Analytical Technology for Real-Time Monitoring of Pharmaceutical Bioconjugation Reactions | Hydrophobic InteractionProteomix HIC@AntibodyHIC, PAT, Bioconjugation, MALSHPLC11
LR2025031560 | Literature Reference: Comparative Structure Activity Relationship Characterization of the Biosimilar BAT1806/BIIB800 to Reference Tocilizumab | Ion ExchangeProteomixIEXHPLC11
MMH1000 | Sepax Monomix H2P SAX Tween Quantification | MMMonomix H2P-SAXTween QuantificationHPLC11
MMH1001 | Quantitative Analysis of Tween 20 in Formulated MAb Samples Using Sepax Mix-Mode SAX Column | MMMonomix H2P-SAXMixed-Mode ChromatographyHPLC11
MML1001 | Sepax Monomix H2P SAX Poloxamer | MMMonomix H2P-SAXtween quantification by PoloxamerHPLC11
MMO1001 | Isolation and Purification of Boron-containing Compounds with Sepax Monomix MC30-Aminodiol | Size Exclusion@Reversed PhaseMonomix MC30-AminodiolIsolation and PurificationHPLC11
Monomix-Core | Sepax Monomix Core Mixed Mode Resin Application | SECMonomix CoremRNA SeparationHPLC@FPLC11
monomix-dt20 | Sepax Monomix dT20 Affinity Resin | SECSRTmRNA SeparationHPLC@FPLC11
MX110 | Monomix Mab60-SP Strong Cation Exchange | Ion ExchangeMonomix Mab60-SPCation ExchangeHPLC11
NQ1001 | Photosynthetic Reaction Center in 0.1% LDAO Detergent-SEC Analysis | Size ExclusionNanofilm@SRT@SRT-CPacking ChemistryHPLC11
NQ1002 | BSA (66 kD) in 0.1% LDAO | Size ExclusionSRT@NanofilmBSAHPLC11
NQ1003 | Ferritin (440 kD) in 0.1% UDM | Size ExclusionSRT@NanofilmFerritinFPLC11
NQ1004 | Membrane protein Aqpz separation in Octyl glucoside | Size ExclusionNanofilm@Zenix@SRTAqpz separationHPLC11
OD1001 | Separation of a Nucleotide mixture on HP-C18 | Reversed PhaseHP-C18Nucleotide Analysis@ResolutionHPLC@LCMS11
OF1001 | Analysis of Melamine on HP-C18 | Reversed PhaseHP-C18Resolution@Volatile Buffer HPLC@LCMS11
OH1001 | Analysis of Florfenicol on HP-C18 | Reversed PhaseHP-C18Resolution@Volatile Buffer HPLC@LCMS12
OH1002 | Analysis of Cyclic Adenosine Monophosphate (cAMP) on HP-C18 | Reversed PhaseHP-C18Cyclic Adenosine MonophosphateHPLC12
OH1003 | Analysis of Valsartan on HP-C18 | Reversed PhaseHP-C18ValsartanHPLC12
OH1004 | Analysis of Vitamins B6 and B12 on HP-C18 | Reversed PhaseHP-C18Vitamins B6 and B12HPLC12
OH1005 | Analysis of Amoxicillin on HP-C18 | Reversed PhaseHP-C18Resolution HPLC@LCMS12
OH1006 | Analysis of Validamycin A on HP-C18 | Reversed PhaseHP-C18Resolution HPLC@LCMS12
OH1007 | Analysis of Roxithromycin on HP-C18 | Reversed PhaseHP-C18Resolution HPLC@LCMS12
OH1008 | Analysis of Gentiopicroside on HP-C18 | Reversed PhaseHP-C18Resolution@Volatile Buffer HPLC@LCMS12
OH1009 | Analysis of Mushroom extract on HP-C18 | Reversed PhaseHP-C18Resolution@Volatile Buffer HPLC@LCMS12
OH1012 | Dicyandiamide and Melamine Analysis on HP-SCX | Reversed PhaseHP-SCXResolution@Volatile Buffer HPLC@LCMS12
OH1013 | Green Tea Extra Purification on HP-C 18 Prep Column | Reversed PhaseHP-C18Resolution@Loading@Volatile Buffer@Fast Assay HPLC@FPLC12
OI1001 | Analysis of Imidacloprid on HP-C18 | Reversed PhaseHP-C18Resolution@Volatile Buffer HPLC@LCMS12
Overview | Sepax Overview | Ion ExchangeZenixSeparation of ProteinsHPLC12
PC1001 | Separation of Carbohydrates in Volatile Buffer on Proteomix SAX | Ion ExchangeProteomixVolatile BufferHPLC@LCMS12
PC1002 | Separation of Glycan and Isomers on Proteomix SAX | Ion ExchangeProteomixResolutionHPLC@LCMS12
PC1003 | Xylo-oligosaccharide on Proteomix SAX | Ion ExchangeProteomixVolatile Buffer@ResolutionHPLC12
PC1004 | High Resolution and Fast Analysis of N-linked Sialylated Glycan by Sepax Proteomix SAX | Ion ExchangeProteomix SAXVolatile Buffer@Resolution@Fast Assay@Particle Size ImpactHPLC@UPLC13
PD1001 | Separation of Oligonucleotide and its impurities by Non Porous vs. Porous | Ion ExchangeProteomixPore Size Selection@ResolutionHPLC13
PD1002 | Separation of Oligonucleotide and its degraded fragments on Proteomix SAX | Ion ExchangeProteomixResolutionHPLC13
PD1003 | DNA Separation on Proteomix WAX | Ion ExchangeProteomixResolutionHPLC13
PD1004 | RNA Separation on Proteomix WAX | Ion ExchangeProteomixResolutionHPLC13
PD1005 | Oligonucleotide Separation on Proteomix SAX | Ion ExchangeProteomixResolutionHPLC13
PD1006 | DNA Separation on Zenix SEC-300 and Proteomix SAX | Size Exclusion@Ion ExchangeProteomix@ZenixResolution@Orthogonal MethodHPLC13
PD1007 | mRNA Separation on SEC and RP | Size Exclusion@Reversed PhaseSRT@ProteomixmRNA SeparationHPLC13
PD1008 | Nucleotide Analysis on Proteomix SAX Column | Ion ExchangeProteomixNucleotide AnalysisHPLC13
PD1009 | Separation of DNA by Proteomix RP Column | Reversed PhaseProteomix RPSeparation of DNAHPLC13
PD1010 | Separation of RNA by Proteomix RP Column | Reversed PhaseProteomix RPSeparation of RNAHPLC13
PD1011 | Separation of Plasmid Isoforms using Anion Exchange Chromatography (AEX) | Ion ExchangeProteomixResolution@Method OptimizationUHPLC@HPLC@FPLC13
PD1012 | Oligonucleotides Analysis using SAX and RP | Ion ExchangeProteomixReversed Phase & Ion ExchangeHPLC13
PE1001 | Separation of Peptide on Proteomix SCX with Volatile Buffer | Ion ExchangeProteomixVolatile BufferHPLC@LCMS13
PE1002 | Analysis of Peptide Digest on Sub 2 µm Proteomix SCX | Ion ExchangeProteomixLoadingHPLC@UHPLC@NanoLC13
PE1003 | Peptide Separation on Proteomix SCX | Ion ExchangeProteomixFast Assay@Method Optimization@Particle Size ImpactHPLC@UHPLC@NanoLC13
PG1001 | Pegylated BSA Separation on SEC and SAX | Size Exclusion@Ion ExchangeProteomix@Zenix@SRTAggregates@Resolution@Loading@Orthogonal Method@Pore Size SelectionHPLC14
PG1002 | Pegylated Protein Separation on SEC and SAX | Size Exclusion@Ion ExchangeProteomix@Zenix@Zenix-CAggregates@Resolution@Orthogonal Method@Pore Size Selection@Packing ChemistryHPLC14
PM1001 | MAb on Proteomix SCX vs. Antibodix WCX NP5 | Ion ExchangeProteomix@AntibodixMethod Optimization@Loading@Resolution@Charge Variants@Packing Chemistry@Competition Comparison HPLC14
PM1002 | MAb on Proteomix SCX NP1.7 vs. NP5 | Ion ExchangeProteomixFast Assay@Particle Size Impact@Charge VariantsHPLC@UHPLC14
PM1003 | MAb fragment on Proteomix WCX NP1.7 | Ion ExchangeProteomixMAb Fragment@Fast Assay@Charge VariantsHPLC@UHPLC14
PM1004 | Fast MAb Analysis on Proteomix SCX - Flow rate | Ion ExchangeProteomixFast Assay@Method Optimization@Charge VariantsHPLC14
PM1005 | MAb on Proteomix vs. Competitor SCX - pH and Salt Gradient | Ion ExchangeProteomixCompetition Comparison@Charge VariantsHPLC14
PM1006 | MAb on Proteomix vs. Competitor SCX - Salt Gradient | Ion ExchangeProteomixCompetition Comparison@Charge VariantsHPLC14
PM1007 | MAb on Proteomix SCX - Flow rate | Ion ExchangeProteomixMethod Optimization@Charge VariantsHPLC14
PM1008 | MAb on Proteomix SCX - pH Gradient | Ion ExchangeProteomixLot to Lot@Method Optimization@Loading@Charge Variants@Fast Assay@Competition ComparisonHPLC14
PM1010 | MAb Carboxypeptidase Digested on Proteomix SCX | Ion ExchangeProteomixMethod Optimization@Charge Variants@Sample Stability TestHPLC14
PM1011 | Herceptin-Cysteine ADC Charge Variants Separation on SCX | Ion ExchangeProteomixCharge VariantsHPLC14
PM1012 | MAb Innovator vs. its Biosimilar on Protoemix SCX | Ion ExchangeProteomixFast Assay@Charge Variants@Orthogonal MethodHPLC@UHPLC14
PM1013 | Intact and Reduced MAb/ADC and MAb Fragment Separation on RP | Reversed PhaseProteomix@Proteomix RPMethod Optimization@Volatile Buffer@Packing Chemistry@Fast Assay@MAb Fragment@Orthogonal MethodHPLC@LCMS@NanoLC14
PM1015 | MAb Fragments on Proteomix RP | Reversed PhaseProteomix RPPore Size Selection@Method Optimization@MAb Fragment@Volatile BufferHPLC/LCMS14
PM1016 | Intact MAb, ADC and their Fragments Analysis on RP LC/MS | Hydrophobic Interaction@Reversed Phase@Reversed PhaseProteomix HIC@Proteomix RPMAb Fragment@Resolution@Volatile Buffer@Method OptimizationHPLC@LCMS14
PM1017 | Monoclonal antibody charge variants separation on Proteomix SCX NP3, UHPLC | Ion ExchangeProteomixFast Assay@Resolution@Method Optimization@Charge VariantsUHPLC15
PM1018 | Column Temperature Effect on mAb Separation on Reversed Phase Chromatography | Reversed PhaseProteomix@Proteomix RPVolatile Buffer@Method Optimization@Resolution@LoadingHPLC@LCMS15
PM1019 | PM1019 - MAb IgG1 and IgG2 Charge Variants Separation by Narrow-bore (2.1 mm I.D.) SCX Column | Ion ExchangeProteomixCharge Variants@Method Optimization@Loading@Resolution@SensitivityHPLC15
PM1020 | NIST MAb Charge Variants Analysis by Cation Exchange Chromatography | Ion ExchangeProteomix@Proteomix SCX@Proteomix WCX@AntibodixMethod Optimization@Charge VariantsHPLC15
PM1021 | Analytical Characterization of NIST MAb by Reversed Phase Chromatography (RP) | Reversed PhaseProteomix RPResolution@Orthogonal MethodHPLC15
PM1022 | Analytical Characterization of NIST MAb by Sepax SEC, HIC, RP and CEX | Ion Exchange@Reversed Phase@Hydrophobic Interaction@Size ExclusionProteomix@Proteomix SCX@Proteomix WCX@Antibodix@Proteomix RP@Proteomix HIC@ZenixMethod Optimization@Resolution@Orthogonal Method@Charge VariantsHPLC15
PM1023 | NIST mAb CEX Separation - Competition Comparison | Ion ExchangeProteomix@Proteomix SCXMethod Optimization@Resolution@Orthogonal Method@Charge VariantsHPLC15
PM1024 | Charge Variants Analysis of CetuximAb with pH Gradient : CEX-HPLC Vendor Comparison | Ion ExchangeProteomixMethod Optimization@Charge VariantsHPLC15
PM1025 | AdalimumAb Charge Variants Separation From Analytical to PrepCation Exchange Chromatography(Humira Innovator and Biosimilar) | Ion ExchangeProteomix@AntibodixCharge Variants@Competition Comparison@Loading, Purification@ResolutionHPLC@FPLC15
PP1001 | Separation of E. Coli Lysate on Proteomix SAX | Ion ExchangeProteomixResolution@Pore Size SelectionHPLC15
PP1002 | High Loading Separation of E. Coli Lysate on Proteomix SAX | Ion ExchangeProteomixLoadingHPLC15
PP1003 | High Peak Capacity Separation of Yeast Lysate on Proteomix SAX | Ion ExchangeProteomixResolution@LoadingHPLC15
PP1004 | Separation of Proteins on Proteomix WCX - Effect of Particle Size | Ion ExchangeProteomix@Proteomix WCXSeparation of ProteinsHPLC15
PP1005 | Separation of Ovalbumin and BSA on Proteomix SAX | Ion ExchangeProteomixResolutionHPLC15
PP1006 | SAX Analysis of Horse Serum on Proteomix vs. Porous | Ion ExchangeProteomixCompetition Comparison@Pore Size SelectionHPLC15
PP1007 | Loading Capacity of RNaseA on Proteomix SCX | Ion ExchangeProteomixLoadingHPLC15
PP1008 | High Resolution of Proteins with different pI on Proteomix SCX | Ion ExchangeProteomixResolutionHPLC16
PP1009 | Analysis of Glycoproteins on Proteomix SAX | Ion ExchangeProteomixResolution@Charge VariantsHPLC16
PP1010 | Intact Glycoprotein Isoforms Separation on Proteomix SAX | Ion Exchange@Size ExclusionProteomix@ZenixResolution@Aggregates@Charge Variants@Method Optimization@Loading@Orthogonal MethodHPLC@LCMS16
PP1011 | Exenatide Acetate Analysis on Proteomix SCX | Ion ExchangeProteomixResolution@Volatile BufferHPLC@LCMS16
PP1013 | Protein Mixture on Sub 2 µm Proteomix SCX | Ion ExchangeProteomixResolution@Fast AssayHPLC@UHPLC16
PP1014 | Protein Mixture on Sub 2 µm Proteomix WCX | Ion ExchangeProteomixResolution@Fast AssayHPLC@UHPLC16
PP1015 | Particle Size Impact for Proteomix SCX | Ion ExchangeProteomixParticle Size ImpactHPLC16
PP1016 | Particle Size Impact for Proteomix WCX | Ion ExchangeProteomixParticle Size ImpactHPLC16
PP1017 | Lot to Lot Consistency for Sub 2 µm Proteomix SCX | Ion ExchangeProteomixLot to Lot@Fast AssayHPLC@UHPLC16
PP1018 | Lot to Lot Consistency for Sub 2 µm Proteomix WCX | Ion ExchangeProteomixLot to Lot@Fast AssayHPLC@UHPLC16
PP1019 | Lifetime Test on 2 µm Proteomix SCX | Ion ExchangeProteomixColumn StabilityHPLC@UHPLC16
PP1021 | HSA Fusion Protein Analysis on Proteomix SAX | Ion ExchangeProteomixResolutionHPLC16
PP1023 | Human Serum on Zenix-C 300 and Proteomix SAX-NP3 | Size Exclusion@Ion ExchangeZenix-C@ProteomixHuman SerumHPLC16
PP1024 | Protein Separation on Proteomix SCX - Volatile buffer | Ion ExchangeProteomixVolatile Buffer@Resolution HPLC/LCMS16
PP1025 | Proteomix RP-1000 Lot to Lot Consistency Study | Reversed PhaseProteomix RPLot to Lot@Volatile BufferHPLC/LCMS16
PP1026 | Fc Fusion Protein Separation on Sepax Proteomix SAX Columns | Ion ExchangeProteomixFusion Protein SeparationHPLC16
PP1027 | Literature Reference: Proteomix SAX Separation of EPO Charge Isomers | IEXProteomixLC/MSLC/MS@HPLC17
PP1028 | Literature Reference: Characterization of Human Serum Albumin Isoforms by Ion Exchange Chromatography Coupled On-line To Native Mass Spectrometry | IEXProteomixLC/MSLC/MS@HPLC17
PV1001 | Improving Empty and Full AAV Capsids Separation and Quantitation with UV-MALS | Ion ExchangeProteomix AAV SAXAdeno-associated virusesHPLC17
PV1002 | IEX-MALS Quantitative Method for AAV Separation by Proteomix AAV SAX Column | Ion ExchangeProteomix AAV SAXAdeno-associated virusesHPLC17
QP1001 | Protein Separation on Proteomix RP-1000 Reversed Phase Column | Reversed PhaseProteomix RPVolatile BufferHPLC@LCMS17
RH1001 | Analysis of Mezlocillin Sodium on SRT-C SEC-100 | Size ExclusionSRT-CResolution HPLC17
RM1001 | MAb on SRT-C SEC | Size ExclusionSRT-CAggregates@ResolutionHPLC17
RP1001 | Protein Loading Capacity Study on SRT-C 300 | Size ExclusionSRT-CLoadingHPLC17
RP1003 | SRT-C Stability Test for Protein | Size ExclusionSRT-CColumn StabilityHPLC17
RQ1002 | Membrane protein Aqpz in Octyl glucoside Detergent-SEC Analysis | Size ExclusionNanofilm@Zenix@SRT-CPacking ChemistryHPLC17
RQ1003 | BSA in 0.1% LDAO-SEC Analysis | Size ExclusionNanofilm@SRT-C@SRTPacking Chemistry@Pore Size SelectionHPLC17
RQ1005 | BSA in 0.02% TDM Analysis-SEC Analysis | Size ExclusionSRT-CPacking Chemistry@AggregatesHPLC17
s41596-020-0304-x | Literature Reference: Generation of synthetic nanobodies against delicate proteins | Size ExclusionSRT-10CPurificationFPLC17
SB1001 | Pore Size Selection on Lysate Separation on SRT | Size ExclusionSRTPore Size SelectionHPLC17
SE1001 | Separation of Peptide and Protein Mixture on SRT | Size ExclusionSRTPore Size SelectionHPLC17
Sepax_mRNA2022 | mRNA HPLC Analysis on SEC, RP, Affinity, and IEX | SECSRT@Proteomix RPmRNA SeparationHPLC17
SF1001 | Heparin SEC Analysis on SRT SEC | Size ExclusionSRTResolutionHPLC18
SG1001 | 39 kD PEGylated Protein Analysis on SRT SEC-150 and SEC-300 | Size Exclusion@Size ExclusionSRTPore Size Selection@Resolution@AggregatesHPLC18
SL1001 | Separation of Polysaccharides on SRT | Size ExclusionSRTCompetition Comparison@Pore Size SelectionHPLC18
SL1002 | Low MW Polysaccharides on SRT SEC-100 and 150 | Size ExclusionSRTPore Size SelectionHPLC18
SL1003 | PEG Analysis on SRT-150 and SRT-300 | Size ExclusionSRTPore Size SelectionHPLC18
SL1004 | Separation of Dextran on SRT-300 | Size ExclusionSRTPore Size SelectionHPLC18
SL1005 | Separation of Pullulan on SRT-300 | Size ExclusionSRTPore Size SelectionHPLC18
SM1001 | MAb on SRT SEC - LMW & HMW regions | Size ExclusionSRTLoading@Resolution@AggregatesHPLC18
SM1002 | MAb & IgG on SRT SEC | Size ExclusionSRTResolutionHPLC18
SM1003 | Sepax SEC Analytical Column Loading Capacity | Size Exclusion@Size ExclusionSRT@ZenixLoadingHPLC18
SM1004 | mAb purification on SRT SEC-300 21.1x300 mm | Size ExclusionSRTResolution@Purification@Aggregates@Fast AssayFPLC18
SM1015 | MAb Purification on SRT-10 300 | Size ExclusionSRT-10Resolution@Loading@Competition Comparison@Method Optimization@AggregatesFPLC18
SM1016 | IgM from Mouse Ascites on SRT SEC-500 | Size ExclusionSRTResolutionHPLC18
SP1001 | Separation of Thyroglobulin and Aggregates on SRT-1000 | Size ExclusionSRTAggregatesHPLC18
SP1002 | Separation of Human Recombinant Protein on SRT-1000 | Size ExclusionSRTResolutionHPLC18
SP1003 | Protein Separation Profiles on SRT-10 Phase | Size ExclusionSRT-10Pore Size SelectionHPLC@FPLC18
SP1004 | The Column Length Impact on Separation Efficiency | Size ExclusionSRT-10ResolutionHPLC@FPLC19
SP1005 | From Analytical to Semi-Prep Separation on SRT-10 | Size ExclusionSRT-10ResolutionHPLC@FPLC19
SP1006 | Protein Separation in Organic Buffer on SRT | Size ExclusionSRTVolatile BufferHPLC@LCMS19
SP1007 | Analysis of Insulin on SRT SEC-150 | Size ExclusionSRTAggregatesHPLC19
SP1008 | EPO Analysis on SRT SEC-300 | Size ExclusionSRTResolutionHPLC19
SP1011 | Protein on SRT SEC-300 5 µm vs 10 µm-Particle Size Impact | Size Exclusion@Size ExclusionSRT@SRT-10Resolution@Particle Size Impact@Fast AssayHPLC@FPLC19
SP1012 | SEC-300 Overlay with Different Particle Sizes -QC standard overlays with 3, 5, 10 mm SEC-300, 7.8 x 300 mm | Size ExclusionSRT@Zenix@SRT-10Resolution@Method OptimizationHPLC19
SP1013 | Small Protein Purification on SRT-10 100Å SEC Prep Size Column | Size ExclusionSRT-10Pore Size Selection@Resolution@Fast Assay@PurificationFPLC19
SP1019 | Preparative SEC Protein Separation by SRT-10 | Size ExclusionSRT-10Resolution@Loading@Fast AssayHPLC@FPLC19
SP1021 | Complex Protein Sample Mixtures Analysis on Sepax Columns | Size Exclusion@Size Exclusion@Size Exclusion@Size Exclusion@Size Exclusion@Ion Exchange@Ion Exchange@Ion Exchange@Reversed Phase@Reversed PhaseSRT@Zenix@Proteomix@Proteomix RPResolution@Pore Size Selection@LoadingHPLC19
SP1022 | Fast Protein Purification with 5 cm ID Large Preparative Size SRT-10 SEC Column | Size ExclusionSRT-10Purification@Particle Size Impact@Fast Assay@Loading@ResolutionHPLC19
SQ1002 | Ferritin in 0.1% UDM-SEC Analysis | Size ExclusionNanofilm@SRT-C@SRTPacking ChemistryHPLC19
SQ1003 | Membrane Protein Separation on Size Exclusion | Size Exclusion@Size Exclusion@Size Exclusion@Size Exclusion@Size Exclusion@Size Exclusion@Size Exclusion@Size Exclusion@Size Exclusion@Size ExclusionSRT@SRT-C@NanofilmPore Size Selection@Packing Chemistry@Resolution@AggregatesHPLC19
SR1001 | Separation of High Molecular Weight RNA on Wide Pore SEC Column | Size ExclusionSRTRNA Separation on Wide Pore ColumnHPLC19
SR1002 | Sepax Circular RNA Separation by SEC and RP Methods | Size ExclusionSRTSEC@Affinity@IEX@HIC@RP@Service@Size Exclusion@Reversed Phase@HPLCHPLC19
SR1003 | Cas9 mRNA and FLuc mRNA | SECSRTmRNA Separation on Size Exclusion ChromatographyHPLC19
SR1004 | Cas9 mRNA Analysis | SECSRTmRNA Separation on Size Exclusion ChromatographyHPLC20
SV1001 | Vaccine Analysis on SRT-2000 | Size ExclusionSRTResolutionHPLC20
SV1002 | Analysis of a Virus Like Particle (VLP) on SRT SEC | Size ExclusionSRTPore Size SelectionHPLC20
SV1005 | LDL, HDL and VLDL on SRT-1000 | Size ExclusionSRTResolution@Pore Size SelectionHPLC20
SV1006 | SV1006: VLP analysis on Large Pore Size SEC-MALS | Size ExclusionSRTSize Exclusion@Pore Size Selection@Aggregates@SEC-MALS@Packing ChemistryHPLC20
SV1007 | Adeno-Associated Virus (AAV5) Separation with Sepax SEC columns | Size ExclusionSRTPore Size Selection@Method OptimizationHPLC20
SZ1001 | Large Pore SEC (1000 Å and 2000 Å) for Large Biomolecule Separation | Size ExclusionSRTPore Size Selection@Column StabilityHPLC20
UNIXP1002 | Unix 1.8 µm UHPLC SEC for Fast Ultra High Resolution Biomolecule Separation | Size ExclusionUnixResolution@Aggregates@Fast Assay@Column Stability@Lot to Lot@Particle Size Impact@LoadingHPLC@UHPLC20
VM1001 | MAb Purification and Aggregates Removal on Generik MC30-HIC Butyl | Ion ExchangeGenerik MC-HICResolution@Purification@AggregatesHPLC@FPLC20
WM1001 | MAb Separation on Unix-C SEC-300 UHPLC Column | Size ExclusionUnix-CResolution@Aggregates@Column Stability@Lot to Lot@Particle Size Impact@LoadingUHPLC20
WM1002 | ADC Separation on Unix-C SEC-300 | Size ExclusionUnix-CResolution@Aggregates@Competition Comparison@Column Stability@Lot to Lot@Particle Size Impact@LoadingUHPLC20
WM1003 | Fast Monoclonal Antibody Titer Determination Followed by SEC Aggregation Analysis | Size ExclusionProtein A-Sil@Unix-CResolution@Fast Assay@Particle Size Impact@AggregatesHPLC@UHPLC20
WP1001 | Fusion Protein Enbrel Separation on Unix-C UHPLC SEC Column | Size ExclusionUnix-CResolution@Aggregates@Competition Comparison@Column Stability@Lot to Lot@Particle Size Impact@LoadingUHPLC20
ZB1001 | Separation of E. Coli Lysate on Various Zenix Pore Sizes | Size ExclusionZenixPore Size SelectionHPLC20
ZC1001 | Tremella Polysaccharide Analysis on Zenix SEC | Size ExclusionZenixPore Size SelectionHPLC20
ZD1001 | Oligonucleotides Analysis using Zenix-C SEC-100 | Size ExclusionZenix-CASO, siRNA, ssRNAHPLC20
ZE1001 | Separation of Proteins and Peptide on Zenix Mixture | Size ExclusionZenixPore Size SelectionHPLC21
ZE1002 | Analysis of Peptide Mixture on Zenix SEC -100 | Size ExclusionZenixResolution@Volatile BufferHPLC@LCMS21
ZE1004 | Competition Comparison for Peptide Separation on SEC | Size ExclusionZenixCompetition ComparisonHPLC21
ZE1005 | Analysis of 5kD and 8kD Peptides by Zenix SEC-150 | Size ExclusionZenixResolutionHPLC21
ZE1006 | Four Peptide Mixture from 1kD to 6kD on Zenix SEC-80 | Size ExclusionZenixResolution@Volatile BufferHPLC@LCMS21
ZE1007 | Analysis of E.coli Tryptic Digest on Zenix SEC-80 | Size ExclusionZenixResolutionHPLC21
ZE1008 | Separation of 13.7 KD to 120 Da Peptide on Zenix-80 | Size ExclusionZenixResolutionHPLC21
ZE1009 | Analysis of Exenatide and Pegylated Exenatide on Zenix and Zenix-C SEC | Size ExclusionZenix@Zenix-CPacking Chemistry@Aggregates@Volatile Buffer@ResolutionHPLC@LCMS21
ZE1012 | Separation of Peptides and Small Proteins using Zenix SEC-100 | Size ExclusionZenixColumn Stability@Resolution@AggregatesHPLC21
ZG1001 | PEGylated Protein Analysis on Zenix | Size ExclusionZenixResolution@AggregatesHPLC21
ZH1001 | Analysis of Antibiotics Biapenem on Zenix SEC-100 | Size ExclusionZenixResolution@Sample Stability Test HPLC21
ZH1002 | Analysis of Cefotaxime Sodium on Zenix SEC-100 | Size ExclusionZenixResolution HPLC21
ZH1003 | LMW Heparin-Dalteparin and Enoxaparin Analysis on Zenix SEC-100 | Size ExclusionZenixResolutionHPLC21
ZJ1001 | Light Scattering Detection of BSA on Zenix SEC-300 | Size ExclusionZenixResolutionHPLC21
ZL1001 | PEG Separation on Zenix SEC | Size ExclusionZenixResolutionHPLC21
ZL1002 | PEG Separation on two Zenix Columns in Tandem | Size ExclusionZenixResolutionHPLC21
ZL1003 | Polystyrene Sulfonate Polymer Separations on SEC | Size ExclusionZenix@SRTPore Size SelectionHPLC22
ZL1004 | Water Soluble Polymer Separation on SEC Columns | Size Exclusion@Size Exclusion@Size Exclusion@Size Exclusion@Size Exclusion@Size Exclusion@Size Exclusion@Size Exclusion@Size Exclusion@Size Exclusion@Size Exclusion@Size Exclusion@Size ExclusionZenix@SRTPore Size Selection@ResolutionHPLC22
ZM1001 | Reproducibility for MAb Analysis on Zenix SEC | Size ExclusionZenixLot to LotHPLC22
ZM1002 | MAb High Resolution by Zenix SEC | Size ExclusionZenixAggregates@ResolutionHPLC22
ZM1003 | Fast MAb analysis by Zenix SEC | Size ExclusionZenixFast AssayHPLC22
ZM1004 | BevacizuMAb and Erbitux Antibodies by Zenix SEC-300 | Size ExclusionZenixAggregates@ResolutionHPLC22
ZM1005 | MAb Fragments Analysis on Zenix SEC-150 | Size ExclusionZenixMAb FragmentHPLC22
ZM1006 | MAb Heavy chain and Light Chain Separation by Zenix SEC | Size ExclusionZenixMAb Fragment@Volatile BufferHPLC@LCMS22
ZM1008 | MAb Fragments Separation and Characterization by SEC and SEC/MS | Size ExclusionZenixMAb Fragment@Volatile Buffer@Method OptimizationHPLC@LCMS22
ZM1011 | Fresh MAb Analysis on Zenix 300 | Size ExclusionZenixAggregates@Sample Stability TestHPLC22
ZM1017 | High Loading of MAb Fragments on Zenix 300 | Size ExclusionZenixMAb Fragment@LoadingHPLC22
ZM1018 | MAb and its ADCs Separation on SEC | Size ExclusionZenix@Zenix-CResolution@Packing Chemistry@Aggregates@Method OptimizationHPLC22
ZM1019 | Analytical Characterization of Antibody Drug Conjugates | Size Exclusion@Ion Exchange@Reversed PhaseZenix-C@Proteomix@Proteomix RPMethod Optimization@Volatile Buffer@Packing Chemistry@Fast Assay@MAb Fragment@Charge Variants@Aggregates@Resolution@Competition Comparison@Orthogonal MethodHPLC@LCMS22
ZM1020 | MAb Half Body TCEP Disulfide reduction | Size ExclusionZenixCompetition Comparison@MAb FragmentHPLC22
ZM1021 | Fast MAb Analysis on Zenix SEC - Flow rate | Size ExclusionZenixFast Assay@Aggregates@Method Optimization@ResolutionHPLC22
ZM1022 | MAb/ADC Fragment Separation after IDeS Digestion | Size Exclusion@Size Exclusion@Hydrophobic Interaction@Reversed PhaseZenix@Zenix-C@Proteomix HIC@Proteomix RPMAb Fragment@Resolution@Volatile BufferHPLC/LCMS22
ZM1023 | ADC vs. Free Drug Analysis | Size Exclusion@Size Exclusion@Size ExclusionZenix@Zenix-CResolution@Volatile Buffer@Pore Size Selection@Fast Assay@Method Optimization@Loading HPLC@LCMS23
ZM1024 | Intact MAb, ADC and their Fragment Analysis with SEC-MS | Size Exclusion@Size Exclusion@Size Exclusion@Size ExclusionZenix@Zenix-CMAb Fragment@Resolution@Volatile Buffer@Method Optimization HPLC@LCMS23
ZM1025 | IgE and IgG Separation on Zenix SEC-300 | Size ExclusionZenixResolution@AggregatesHPLC23
ZM1026 | Reduced MAb Separation on Zenix SEC-300 2.1x300 with LC/MS Volatile Buffer | Size ExclusionZenixLoading@Resolution@Volatile BufferHPLC@LCMS23
ZM1027 | Analytical Characterization of NIST MAb by Size Exclusion Chromatography | Size ExclusionZenixMethod Optimization@Resolution@Orthogonal MethodHPLC23
ZM1028 | Custom Affinity Using HSA as the Immobilized Ligand to Assess mAb Immunogen Cross-Reactivity | AffinityZenixResolution@Orthogonal MethodHPLC@FPLC23
ZM1029 | Custom Affinity Using HSA as the Immobilized Ligand to Assess mAb Immunogen Cross-Reactivity | AffinityZenixResolution@Orthogonal MethodHPLC@FPLC23
ZP1001 | 3 & 5 µm SEC on Separation Efficiency | Size ExclusionZenix@SRTParticle Size ImpactHPLC23
ZP1002 | Improved Resolution on 3 µm SEC | Size ExclusionSRT@ZenixParticle Size ImpactHPLC23
ZP1003 | MW Calibration Curve on Zenix Phases | Size ExclusionZenixPore Size SelectionHPLC23
ZP1004 | Separation of Bio-Rad Protein Mixture by Zenix | Size ExclusionZenixPore Size SelectionHPLC23
ZP1005 | Separation of Protein Mixture by Zenix Phases | Size ExclusionZenixPore Size SelectionHPLC23
ZP1007 | Fast Assay Application on Zenix-300 | Size ExclusionZenixFast AssayHPLC23
ZP1008 | Fast Separation of Horse Serum by Zenix | Size ExclusionZenixFast AssayHPLC23
ZP1009 | Analysis of Fc Fusion Protein on Zenix vs. SRT | Size ExclusionZenix@SRTParticle Size ImpactHPLC23
ZP1010 | Separation of Asparaginase on Zenix SEC-150 | Size ExclusionZenixResolution@AggregatesHPLC23
ZP1011 | Lysozyme Elution Profiles on Zenix | Size ExclusionZenixMethod OptimizationHPLC24
ZP1018 | Life Time Test of Zenix 300 with High Salt at pH 8.5 | Size ExclusionZenixColumn StabilityHPLC24
ZP1019 | Protein Separation on Zenix SEC-300 with HPLC and FPLC system | Size ExclusionZenixResolutionFPLC@HPLC24
ZP1020 | rhEPO (CHO cell) Separation on Zenix SEC-150 | Size ExclusionZenixResolutionHPLC24
ZY1002 | E. Coli Lysate separation on SEC, SAX and RP | Size Exclusion@Ion Exchange@Reversed PhaseProteomix@Proteomix RP@Zenix@ProteomixResolution@Pore Size Selection@Loading@Orthogonal MethodHPLC@LCMS24
ZZ1001 | Vaccine Analysis on SRT-2000 | Size ExclusionSRTPore Size Selection@Column StabilityHPLC24
ZZ1003 | Fast Separation of MAb and its Aggregates in Less Than 3 Mins | Size ExclusionZenixFast Assay@Lot to LotHPLC24
ZZ1004 | SEC Separation of Protein Mixtures on SRT and TSKgel | Size ExclusionSRTCompetition Comparison@ResolutionHPLC24
ZZ1006 | Oligonucleotide Separation on SEC, IEX and RP Columns | Ion Exchange@Ion Exchange@Reversed Phase@Size Exclusion@Size Exclusion@Size ExclusionZenix@Proteomix@Zenix-C@Proteomix RPResolution@Method Optimization@Pore Size Selection@Packing Chemistry@Orthogonal MethodHPLC24
ZZ10061 | Peptide Separations Using Zenix SEC-80 | Size ExclusionZenixMethod Optimization@ResolutionHPLC24
ZZ1007 | E.Coli Tryptic Digest on Zenix SEC-80 | Size ExclusionZenixResolutionHPLC24
ZZ1008 | SEC Column Selection Guide for Water-soluble Polymers | Size ExclusionSRTPore Size SelectionHPLC24
ZZ1009 | Zenix and Zenix-C SEC-80 for Peptide Analysis | Size ExclusionZenixVolatile Buffer@Packing Chemistry@Volatile BufferHPLC@LCMS@NanoLC24